<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <sponsors>
      <item>
        <fullName>Rep. Pocan, Mark [D-WI-2]</fullName>
        <lastName>Pocan</lastName>
        <bioguideId>P000607</bioguideId>
        <party>D</party>
        <middleName />
        <state>WI</state>
        <firstName>Mark</firstName>
        <district>2</district>
        <byRequestType />
        <identifiers>
          <lisID>2171</lisID>
          <bioguideId>P000607</bioguideId>
          <gpoId />
        </identifiers>
      </item>
    </sponsors>
    <laws />
    <version>1.0.0</version>
    <introducedDate>2017-06-21</introducedDate>
    <cboCostEstimates />
    <titles>
      <item>
        <chamberCode />
        <chamberName />
        <parentTitleType />
        <titleType>Short Titles as Introduced</titleType>
        <title>Stop Price Gouging Act</title>
      </item>
      <item>
        <chamberCode />
        <chamberName />
        <parentTitleType />
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Internal Revenue Code of 1986 to establish an excise tax on certain prescription drugs which have been subject to a price spike, and for other purposes.</title>
      </item>
      <item>
        <chamberCode />
        <chamberName />
        <parentTitleType />
        <titleType>Display Title</titleType>
        <title>Stop Price Gouging Act</title>
      </item>
      <item>
        <chamberCode />
        <chamberName />
        <parentTitleType />
        <titleType>(Extracted from GPO) Short Titles as Introduced</titleType>
        <title>Stop Price Gouging Act</title>
      </item>
    </titles>
    <amendments />
    <recordedVotes />
    <relatedBills>
      <item>
        <congress>115</congress>
        <latestAction>
          <actionDate>2017-06-15</actionDate>
          <text>Read twice and referred to the Committee on Finance.</text>
        </latestAction>
        <type>S</type>
        <latestTitle>Stop Price Gouging Act</latestTitle>
        <number>1369</number>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <constitutionalAuthorityStatementText><![CDATA[<pre>From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. POCAN:H.R. 2974.Congress has the power to enact this legislation pursuantto the following:To regulate Commerce with foriegn Nations, and among severlStates, and with the Indian Tribes.[Page H5048]</pre>]]></constitutionalAuthorityStatementText>
    <billType>HR</billType>
    <actions>
      <actionByCounts>
        <houseOfRepresentatives>5</houseOfRepresentatives>
      </actionByCounts>
      <item>
        <actionDate>2017-06-23</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <committee>
          <name>Ways and Means Committee</name>
          <systemCode>hswm00</systemCode>
        </committee>
        <actionCode>H11100</actionCode>
        <actionDate>2017-06-21</actionDate>
        <links />
      </item>
      <item>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <actionCode>H11100</actionCode>
        <actionDate>2017-06-21</actionDate>
        <links />
      </item>
      <item>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <committee />
        <actionCode>Intro-H</actionCode>
        <actionDate>2017-06-21</actionDate>
        <links />
      </item>
      <item>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <committee />
        <actionCode>1000</actionCode>
        <actionDate>2017-06-21</actionDate>
        <links />
      </item>
      <actionTypeCounts>
        <introducedInHouse>1</introducedInHouse>
        <billReferrals>2</billReferrals>
        <placeholderTextForH>1</placeholderTextForH>
        <introducedInTheHouse>1</introducedInTheHouse>
      </actionTypeCounts>
    </actions>
    <notes />
    <originChamber>House</originChamber>
    <congress>115</congress>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Business records</name>
          </item>
          <item>
            <name>Congressional oversight</name>
          </item>
          <item>
            <name>Government information and archives</name>
          </item>
          <item>
            <name>Government studies and investigations</name>
          </item>
          <item>
            <name>Inflation and prices</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
          <item>
            <name>Sales and excise taxes</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Taxation</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <billNumber>2974</billNumber>
    <cosponsors>
      <item>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <fullName>Rep. Kaptur, Marcy [D-OH-9]</fullName>
        <middleName />
        <sponsorshipDate>2017-06-21</sponsorshipDate>
        <bioguideId>K000009</bioguideId>
        <lastName>KAPTUR</lastName>
        <party>D</party>
        <district>9</district>
        <firstName>MARCY</firstName>
        <state>OH</state>
        <identifiers>
          <gpoId>8099</gpoId>
          <bioguideId>K000009</bioguideId>
          <lisID>616</lisID>
        </identifiers>
        <sponsorshipWithdrawnDate />
      </item>
      <item>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <fullName>Rep. Jayapal, Pramila [D-WA-7]</fullName>
        <middleName />
        <sponsorshipDate>2017-09-07</sponsorshipDate>
        <bioguideId>J000298</bioguideId>
        <lastName>Jayapal</lastName>
        <party>D</party>
        <district>7</district>
        <firstName>Pramila</firstName>
        <state>WA</state>
        <identifiers>
          <gpoId />
          <lisID>2354</lisID>
          <bioguideId>J000298</bioguideId>
        </identifiers>
        <sponsorshipWithdrawnDate />
      </item>
      <item>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <fullName>Rep. Khanna, Ro [D-CA-17]</fullName>
        <middleName />
        <sponsorshipDate>2018-02-08</sponsorshipDate>
        <bioguideId>K000389</bioguideId>
        <lastName>Khanna</lastName>
        <party>D</party>
        <district>17</district>
        <firstName>Ro</firstName>
        <state>CA</state>
        <identifiers>
          <lisID>2308</lisID>
          <bioguideId>K000389</bioguideId>
          <gpoId />
        </identifiers>
        <sponsorshipWithdrawnDate />
      </item>
      <item>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <fullName>Rep. Payne, Donald M., Jr. [D-NJ-10]</fullName>
        <middleName>M.</middleName>
        <sponsorshipDate>2018-02-08</sponsorshipDate>
        <bioguideId>P000604</bioguideId>
        <lastName>Payne</lastName>
        <party>D</party>
        <district>10</district>
        <firstName>Donald</firstName>
        <state>NJ</state>
        <identifiers>
          <bioguideId>P000604</bioguideId>
          <gpoId>8373</gpoId>
          <lisID>2097</lisID>
        </identifiers>
        <sponsorshipWithdrawnDate />
      </item>
    </cosponsors>
    <summaries>
      <billSummaries>
        <item>
          <versionCode>00</versionCode>
          <updateDate>2017-06-21T04:00:00Z</updateDate>
          <actionDate>2017-06-21</actionDate>
          <text><![CDATA[<p><b>Stop Price Gouging Act </b></p> <p>This bill amends the Internal Revenue Code to impose an excise tax on pharmaceutical companies that sell prescription drugs that are subject to price spikes that exceed the annual percentage increase in the medical care consumer price index detailed expenditure category for all urban consumers (U.S. city average). </p> <p>For each taxable prescription drug, the excise tax ranges from 50% to 100% of price spike revenue received by the company, depending on the size of the price spike and including an adjustment for revenue that is due solely to an increase in the cost of the inputs necessary to manufacture the drug. </p> <p>Pharmaceutical companies must submit specified data regarding drug prices and revenue to the Inspector General (IG) of the Department of Health and Human Services (HHS), and the IG must submit an assessment of the data to the Internal Revenue Service.</p> <p>HHS, upon the recommendation of the IG, may exempt certain drugs from the excise tax if: (1) a for-cause price increase exemption should apply; (2) the drug has an average manufacturer price of not greater than $10 for a 30-day supply; and (3) the drug is marketed by at least 3 other holders of applications approved under the Federal Food, Drug, and Cosmetic Act. </p> <p>The Government Accountability Office must examine: (1) how drug manufacturers and health plans establish initial launch prices for newly approved drugs, and (2) alternative methods that have been proposed for setting the price of new drugs. </p>]]></text>
          <actionDesc>Introduced in House</actionDesc>
          <lastSummaryUpdateDate>2017-11-02T15:28:36Z</lastSummaryUpdateDate>
          <name>Introduced in House</name>
        </item>
      </billSummaries>
    </summaries>
    <policyArea>
      <name>Taxation</name>
    </policyArea>
    <latestAction>
      <links />
      <actionDate>2017-06-23</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
    <updateDate>2018-02-09T13:00:48Z</updateDate>
    <committees>
      <billCommittees>
        <item>
          <systemCode>hsif00</systemCode>
          <name>Energy and Commerce Committee</name>
          <type>Standing</type>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2017-06-21T14:01:05Z</date>
            </item>
          </activities>
          <chamber>House</chamber>
          <subcommittees>
            <item>
              <activities>
                <item>
                  <name>Referred to</name>
                  <date>2017-06-23T13:56:39Z</date>
                </item>
              </activities>
              <systemCode>hsif14</systemCode>
              <name>Health Subcommittee</name>
            </item>
          </subcommittees>
        </item>
        <item>
          <systemCode>hswm00</systemCode>
          <name>Ways and Means Committee</name>
          <type>Standing</type>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2017-06-21T14:01:10Z</date>
            </item>
          </activities>
          <chamber>House</chamber>
          <subcommittees />
        </item>
      </billCommittees>
    </committees>
    <createDate>2017-06-22T08:44:31Z</createDate>
    <title>Stop Price Gouging Act</title>
    <committeeReports />
    <calendarNumbers />
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

